Business Context and Reporting Period
This Form 8-K Current Report was filed by MacroGenics, Inc. on September 14, 2016. The filing addresses a change in executive leadership and associated compensatory arrangements.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation details.
- Base Salary Increase: Dr. Ezio Bonvini's annual base salary is increased to $391,000.
- Target Bonus: Eligible for an annual performance bonus with a target of 35% of base salary.
- Equity Grant: 30,000 employee stock options granted.
Material Changes
On September 14, 2016, Ezio Bonvini, M.D., was promoted from Senior Vice President, Research, to the dual role of Senior Vice President, Research and Chief Scientific Officer. This promotion triggered the compensation adjustments noted above.
Outlook, Risks, and Unusual Items
Equity Vesting Schedule: The 30,000 stock options granted to Dr. Bonvini will fully vest over four years, contingent on continued employment. The schedule includes 12.5% vesting six months after the grant date, with the remainder vesting in equal installments over the subsequent 14 quarters.
Related Party Transactions: The filing explicitly states there are no family relationships between Dr. Bonvini and any director or officer, and no related party transactions involving him.
Investor Verification Checklist
- Verify the terms of the Employment Agreement dated March 8, 2016 (Exhibit 10.3 to the Q1 2016 Form 10-Q).
- Confirm the impact of the new Chief Scientific Officer role on the company's research pipeline.
- Review the dilution impact of the 30,000 stock option grant relative to the company's total outstanding shares.